Manuel Praga - Publications

Management of Recurrent C3 Glomerulopathy After Kidney Transplantation.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 11, 2026

Natural History and Progression of Recurrent C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative GN in Kidney Transplantation.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 16, 2026

Natural History and Progression of Recurrent C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative Glomerulonephritis in Kidney Transplantation.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 16, 2026

Development and validation of EULAR quality indicators for lupus nephritis: adherence trends and impact on clinical outcomes.

Journal: Annals of the rheumatic diseases

Published: March 11, 2026

The authors reply.

Journal: Kidney international

Published: February 25, 2026

Delayed kidney response in AL amyloidosis: prevalence and clinical significance.

Journal: Clinical kidney journal

Published: February 04, 2026

Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases.

Journal: Frontiers in immunology

Published: January 31, 2026

The expanding role of complement inhibitors in the treatment of IgA nephropathy.

Journal: Kidney international

Published: December 12, 2025

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Journal: The New England journal of medicine

Published: November 10, 2025

Hematuria as a biomarker guiding treatment decisions in IgA nephropathy? Yes.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: November 07, 2025

Chronic kidney disease progression in glomerular diseases: is hematuria a key risk factor?

Journal: Pediatric nephrology (Berlin, Germany)

Published: October 25, 2025

Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: September 25, 2025